Insulet (PODD) just released new clinical data on its future Omnipod 6 and fully closed loop systems, showing improved glucose control across type 1 and type 2 diabetes patients and reinforcing investor focus on the stock.

The fresh Omnipod 6 and fully closed loop data arrive at a time when Insulet’s 1 day share price return of 4.65% and 7 day return of 5.71% contrast with a 90 day share price decline of 36.26% and a 1 year total shareholder return decline of 50.85%. This suggests recent interest is picking up after a difficult stretch.

If this type of diabetes technology story catches your eye, it can be worth scanning for other healthcare stocks working with artificial intelligence. A starting point is the 39 healthcare AI stocks.

Yet despite the fresh clinical data and a share price that has fallen more than 50% over the past year while still trading below some valuation estimates, you have to ask: is Insulet on sale here, or is the market already discounting future growth?

Most Popular Narrative: 37.1% Undervalued

Insulet's most followed narrative pegs fair value at about $243.78 per share versus a last close of $153.22. This frames a sizeable valuation gap that hinges on future diabetes device adoption and profitability.

Accelerating penetration of the massive, underpenetrated type 2 diabetes segment supported by positive pivotal trial data (SECURE-T2D) and improved access/affordability (broad pharmacy distribution, low co-pays) is a new growth engine that significantly increases Insulet's addressable market and sustains ongoing customer base growth, driving durable revenue streams.

Curious what sits behind that type 2 expansion story? The narrative leans on robust revenue growth, expanding margins, and a future earnings multiple that assumes real staying power.

Result: Fair Value of $243.78 (UNDERVALUED)

However, the story can change quickly if reliance on the Omnipod product or future pricing and reimbursement pressure begins to affect the growth expectations that support this undervalued narrative.

Another Angle on Valuation

The main narrative leans on future earnings and price targets, but today the stock trades on a P/E of about 35x versus a fair ratio of 29.8x and a US Medical Equipment industry average of 25.3x. That is a rich starting point, so is the discount story already on the table?

Next Steps

There is clearly a mix of confidence and caution in the story so far. Move quickly, review the full picture, and weigh both 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Insulet has sharpened your interest, do not stop here. Use the screeners below to quickly surface other stock ideas that could suit your style.

• Target quality at a discount by scanning our list of 49 high quality undervalued stocks that pair fundamentals with pricing that might appeal to value focused investors.
• Prioritise resilience by reviewing 61 resilient stocks with low risk scores that score well on stability so short term swings are less likely to dominate your watchlist.
• Get ahead of the crowd by checking the screener containing 21 high quality undiscovered gems that combine strong financial traits with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.